Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.66 - $1.29 $3,946 - $7,712
-5,979 Reduced 0.61%
981,320 $735,000
Q4 2022

Feb 13, 2023

BUY
$1.1 - $2.45 $12,819 - $28,552
11,654 Added 1.19%
987,299 $1.22 Million
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $27,914 - $47,283
-14,242 Reduced 1.44%
975,645 $2.01 Million
Q2 2022

Aug 12, 2022

BUY
$2.27 - $4.86 $329,018 - $704,418
144,942 Added 17.15%
989,887 $2.74 Million
Q1 2022

May 13, 2022

SELL
$3.69 - $5.65 $182,880 - $280,019
-49,561 Reduced 5.54%
844,945 $3.69 Million
Q4 2021

Feb 08, 2022

BUY
$5.37 - $7.07 $85,957 - $113,169
16,007 Added 1.82%
894,506 $4.94 Million
Q3 2021

Nov 15, 2021

SELL
$5.54 - $7.51 $307,132 - $416,346
-55,439 Reduced 5.94%
878,499 $5.43 Million
Q2 2021

Aug 13, 2021

SELL
$7.78 - $11.4 $169,432 - $248,269
-21,778 Reduced 2.28%
933,938 $7.94 Million
Q1 2021

May 12, 2021

BUY
$5.12 - $8.48 $850,954 - $1.41 Million
166,202 Added 21.05%
955,716 $7.56 Million
Q4 2020

Feb 11, 2021

BUY
$3.16 - $7.03 $127,480 - $283,604
40,342 Added 5.38%
789,514 $4.6 Million
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $24,870 - $36,085
7,629 Added 1.03%
749,172 $2.54 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $42,132 - $123,463
26,666 Added 3.73%
741,543 $3.42 Million
Q1 2020

May 14, 2020

BUY
$1.44 - $3.02 $70,158 - $147,137
48,721 Added 7.31%
714,877 $1.13 Million
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $239,438 - $326,700
106,417 Added 19.01%
666,156 $1.83 Million
Q3 2019

Nov 13, 2019

BUY
$2.67 - $3.65 $1.36 Million - $1.85 Million
507,528 Added 972.07%
559,739 $1.65 Million
Q2 2019

Aug 13, 2019

BUY
$2.6 - $4.21 $135,748 - $219,808
52,211 New
52,211 $150,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.